key: cord-0305932-dti9o5x3
authors: Hoeg, T. B.; Krug, A.; Stevenson, J.; Mandrola, J.
title: SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis
date: 2021-09-08
journal: nan
DOI: 10.1101/2021.08.30.21262866
sha: 21a40722ebdbb77f1e8c61fc2bb0d28746f0b870
doc_id: 305932
cord_uid: dti9o5x3

Objectives: Establishing the rate of post-vaccination cardiac myocarditis in the 12-15 and 16-17-year-old population in the context of their COVID-19 hospitalization risk is critical for developing a vaccination recommendation framework that balances harms with benefits for this patient demographic. Design, Setting and Participants: Using the Vaccine Adverse Event Reporting System (VAERS), this retrospective epidemiological assessment reviewed reports filed between January 1, 2021, and June 18, 2021, among adolescents ages 12-17 who received mRNA vaccination against COVID-19. Symptom search criteria included the words myocarditis, pericarditis, and myopericarditis to identify children with evidence of cardiac injury. The word troponin was a required element in the laboratory findings. Inclusion criteria were aligned with the CDC working case definition for probable myocarditis. Stratified cardiac adverse event (CAE) rates were reported for age, sex and vaccination dose number. A harm-benefit analysis was conducted using existing literature on COVID-19-related hospitalization risks in this demographic. Main outcome measures: 1) Stratified rates of mRNA vaccine-related myocarditis in adolescents age 12-15 and 16-17; and 2) harm-benefit analysis of vaccine-related CAEs in relation to COVID-19 hospitalization risk. Results: A total of 257 CAEs were identified. Rates per million following dose 2 among males were 162.2 (ages 12-15) and 94.0 (ages 16-17); among females, rates were 13.0 and 13.4 per million, respectively. For boys 12-15 without medical comorbidities receiving their second mRNA vaccination dose, the rate of CAE is 3.7-6.1 times higher than their 120-day COVID-19 hospitalization risk as of August 21, 2021 (7-day hospitalizations 1.5/100k population) and 2.6-4.3-fold higher at times of high weekly hospitalization risk (2.1/100k), such as during January 2021. For boys 16-17 without medical comorbidities, the rate of CAE is currently 2.1-3.5 times higher than their 120-day COVID-19 hospitalization risk, and 1.5-2.5 times higher at times of high weekly COVID-19 hospitalization. Conclusions: Post-vaccination CAE rate was highest in young boys aged 12-15 following dose two. For boys 12-17 without medical comorbidities, the likelihood of post vaccination dose two CAE is 162.2 and 94.0/million respectively. This incidence exceeds their expected 120-day COVID-19 hospitalization rate at both moderate (August 21, 2021 rates) and high COVID-19 hospitalization incidence. Further research into the severity and long-term sequelae of post-vaccination CAE is warranted. Quantification of the benefits of the second vaccination dose and vaccination in addition to natural immunity in this demographic may be indicated to minimize harm.

Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273 vaccines for SARS-CoV-2 have demonstrated exceptional safety and real-world effectiveness in preventing severe disease and death from COVID-19. Concerns about vaccination-related myocarditis in young men were initially raised in Israel with rates between 1/3000-1/6000. [1] In the United States, the initial Centers for Disease Control and Prevention (CDC) report [2, 3] identified a rate of approximately . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 8, 2021. ; https://doi.org/10.1101/2021.08.30.21262866 doi: medRxiv preprint 12.6 per million (1/80,000) second doses administered in ages 12-39, but approximately 1/15,000 for males 12-17 and 1/19,000 for males [18] [19] [20] [21] [22] [23] [24] . [2, 3] Although the CDC analyses [2, 3] identified a higher rate of myocarditis in boys than young men, further stratification by adolescent age group (e.g., 12-15 and 16-17 years) was not provided. A second potential limitation was the sensitivity of the CDC symptom search inclusion criteria, which may have failed to identify cases of cardiac adverse events (CAEs), consistent with myocarditis, with objective evidence of cardiac injury following vaccination.

On August 23 rd , the Federal Drug Administration (FDA) released a Pfizer-BioNTech vaccine report [4] which outlines "an excess risk [of myocarditis] approaching 200 cases/million" or 1/5000 in 16-17- year-old boys, which was three times higher than reported by the CDC [2, 3] . In their harm-benefit analysis, the most likely scenario was the benefits of vaccination would outweigh harms in 16-17-year-old males, but "predicted excess cases of vaccine-associated myocarditis/pericarditis would exceed COVID-19 hospitalizations and deaths under the 'worst case' scenario" [4] .

Post-vaccination myocarditis rates for the 12-15-year-old age group had not yet been reported beyond the initial trial with 1131 vaccination recipients [5] , until August 30 th , 2021, when the CDC reported [6] the following rates for boys ages 12-15 and 16-17 within seven days of their second dose of Pfizer-BioNTech at 42.6 and 71.5 per million, respectively. For females, rates were 4.3 and 8.1 per million, respectively. A harm-benefit analysis of vaccination in the pediatric age group has not yet been performed based on presence of absence of underlying medical . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted September 8, 2021. ; https://doi.org/10.1101/2021.08.30.21262866 doi: medRxiv preprint conditions. While medical comorbidities confer higher risk for severe COVID-19, this is not known to be the case for post-vaccination myocarditis.

The CDC [2, 6] reported a 94-96% hospitalization rate for VAERS-identified myocarditis. The CDC used a 120-day COVID-19 hospitalization rate as a meaningful comparator to vaccinationrelated harms, and we have chosen to use this same comparison for our study.

Our primary aim was to stratify post-mRNA vaccination myocarditis by age and vaccination dose within the 12-17-year-old population. Our secondary aim was to provide an updated estimate to complement the CDC's [2, 3, 6] and FDA's [4] findings. Our final aim was to perform a harm-benefit analysis of mRNA COVID-19 vaccination myocarditis with that of COVID-19 hospitalization for children with and without one or more comorbidity at low, moderate, and high 120-day COVID-19 hospitalization rates.

We searched the Vaccine Adverse Event Reporting System (VAERS) data for females and males ages 12-17 in reports processed from 1/1/2021 through 6/18/2021 with diagnoses of "myocarditis," "pericarditis," "myopericarditis" or "chest pain" in the symptom notes and required the term "troponin" in the laboratory data. We defined a CAE using the CDC working case definition for a probable case. [2] Specifically, the symptom of "chest pain" required at least one of the following: diagnosis of myocarditis, peri-or myopericarditis, acute myocardial infarction; elevated troponin; abnormal electrocardiogram (EKG), abnormal echocardiogram (ECHO), or cardiac MRI (cMRI) findings consistent with myocarditis (as defined in Supplement . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted September 8, 2021. ; https://doi.org/10.1101/2021.08.30.21262866 doi: medRxiv preprint 1). Cases and hospitalizations with an unknown dose number were assigned to dose 1 or dose 2 in the same proportion as the known doses: 15% occurred following dose 1 and 85% occurred following dose 2.

To compute crude rates per million for doses 1 and 2, our denominators included all children with at least 1 dose of any vaccination and all fully vaccinated children, respectively, as of 6/11/2021 [6] to accommodate both reporting lag and a pre-defined 7-day risk window, consistent with the CDC's analysis. 95% Poisson confidence intervals were calculated for these rates.

To perform a harm-benefit analysis, pediatric hospitalization rates for COVID-19 were obtained from the CDC's COVID-NET. [7] COVID-19 hospitalization rates among children with and without one or more medical comorbidities were calculated based on hospitalization rates at times of low (June 2021), moderate (August 2021) and high (January 2021) incidence. [8] Children with at least one medical comorbidity were considered to have 4.7 times the likelihood of COVID-19 hospitalization as those without comorbidities based on 70% of children hospitalized for COVID-19 having one or more medical comorbidity. [9] We estimate 33% of children in this age group have one or more comorbidity based upon current data[10] suggesting 21.2% of children 12-19 have obesity and around 8.4% have asthma. [11] These comorbidities are also found in the summary of underlying conditions for pediatric COVID-19 hospitalizations reported to COVID-NET. [8] The two most common underlying conditions among pediatric hospitalizations are obesity (33.8%) and asthma (14.8%). [8] Other relevant comorbidities such as diabetes [11] or the medically complex children [12] appear to make up <5% of this demographic. [11] The estimated ratio of expected hospitalizations for children by presence or . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We provided an additional rate which adjusted for the reported approximate 40% of pediatric hospitalizations for COVID-19 being incidental positive tests on admission. [9, 13, 14] Finally, the risk of post-vaccination CAE post-dose two in 12-15-year-old-boys was compared with their overall risk of hospitalization from COVID-19 according to presence or absence of comorbidities and adjusted for the 40% hospitalization overestimate as well as the asymptomatic fraction of pediatric cases.

A total of 276 reports met our initial search criteria; of these, 18 were excluded because they had no objective evidence of elevated troponins or abnormal findings on ECG/EKG or ECHO, or we could not exclude the possibility of viral myocarditis or concomitant pneumonia. Of the 18 excluded cases, eight were hospitalized. Nine were 12-15 and nine were 16-17 years old. Sixteen of the excluded cases were coded "chest pain" in the symptom notes and the remaining two females were coded as "myocarditis" but no troponin values nor EKG/ECG findings were . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 8, 2021. ; https://doi.org/10.1101/2021.08.30.21262866 doi: medRxiv preprint included. Of the remaining 258 cases, we excluded from sex-specific rates one case with "unknown" sex, leaving 257 cardiac adverse event reports for full analysis (25 females and 232 males). Of these, 211 cases had peak troponin values available for analysis (Supplement 2); 37 reports did not include the vaccine dose number. Of the 257 included cases, 256 had received Pfizer-BioNTech mRNA vaccination, one had received Moderna mRNA vaccination (only Pfizer-BioNTech was approved for vaccination of children <18 at the time of our database search).

The CAE rates by age and sex and vaccination dose are shown in Figure 1 and Table 1 . higher that the CDC's estimate. [2, 6] Among girls 16-17, our estimate was 13.4/million, which was 47-65% higher than the CDC's estimate.

Rates per million following dose 1 among males were: 12.0 per million (ages 12-15) and 8.2 per million (ages [16] [17] . Rates per million following dose 1 among females were 0 (ages 12-15) and 2.0 (ages [16] [17] . With respect to dose 1 and compared to CDC findings, 12-15-year-old boys were 22-150% higher than the CDC, while girls this age had zero CAEs in our analysis. Among adolescents ages 16-17, our rates were 16% lower to 58% higher for boys and 82% higher for . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 8, 2021. ; https://doi.org/10.1101/2021.08.30.21262866 doi: medRxiv preprint girls [2] and in the updated CDC report [6] the reported rate for girls 16 with an unknown dose number were assigned proportionately to the overall distribution among the cases with a known dose number: 5 were assigned to dose one and 32 were assigned to dose two.

In the seven-month period of January 2021-July 2021, the rate of COVID-19 hospitalization among adolescents (ages 12-17) has ranged from a low of ≤ 4 per million weekly (July 2021) to moderate level (15 per million per week in mid-August 2021) and high (21 per million per week in January 2021) ( Figure 6 ). [8, 9] A healthy adolescent might expect a COVID-19 hospitalization . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. hospitalization rate) also exceeds that of their 120-day COVID-19 hospitalization risk even at high hospitalization rates (Figures 6 and 7) . For 12-17-year-old-boys with at least one medical comorbidity ( Figure 6 and 7) their risk of post-vaccination CAE only exceeds their 120-day COVID-19 hospitalization risk at times of low hospitalization rates.

We also performed an adjusted analysis based on 40% of COVID-19 hospitalizations being due to another cause with incidental positive COVID-19 test during the hospitalization [8, 12, 13] . At current moderate incidence, the 120-day hospitalization risk for COVID-19 for a healthy child . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 8, 2021. may be as low as 26.7 per million ( Figure 6 in italics), twice the risk of a CAE after vaccine dose 1 in boys without comorbidities and after dose 2 in girls without comorbidities ( Table 1 ). The risk for boys aged 12-15 with no comorbidities of CAE after dose two would be 22.8 times higher than their COVID-19 hospitalization risk at the adjusted low (7.1/million), 6.1 times higher for moderate (26.7/million) and 4.3 times higher at high (37.3/million) 120-day hospitalization rates (Figures 6 and 7) . The risk for boys [16] [17] with no comorbidities of CAE after dose 2 would be and 13.2 times higher than their COVID-19 hospitalization risk at the adjusted low (7.1/million), 3.5 times higher at moderate (26.7/million) and 2.5 times higher at high (37.3/million) 120-day adjusted hospitalization rates ( Figures 6 and 7) . For 12-15-year-old boys with one or more comorbidity, the vaccine-associated CAE risk following dose two is less than the adjusted COVID-19 hospitalization risk at times of high COVID-19 incidence. For 16-17-year-old boys with one or more comorbidity, the CAE rate was below that of the adjusted COVID-19 hospitalization risks at both current (moderate) and high disease prevalence ( Figure   7 ; Table 1 ).

The main finding of this study was the cardiac adverse event (CAE) rates of 162/million and 94/million post-Pfizer-BioNTech BNT162b2 vaccination dose two for the 12-15-and 16-17year-old boys, respectively. Approximately 86% of these resulted in hospitalization for both age groups. We included a case-finding method in VAERS which utilized the symptom "chest pain" to identify adolescents for review of troponins, EKG/ECG and ECHO findings. We otherwise maintained the specificity of our analysis by requiring the same objective findings of cardiac . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 8, 2021. ; https://doi.org/10.1101/2021.08.30.21262866 doi: medRxiv preprint injury used by the CDC to identify probable cases (Supplement 1) and excluded cases without sufficient objective evidence of cardiac-specific injury.

Using these broader search and inclusion criteria, we found post-vaccination rates of CAEs among adolescents aged 12-17 that exceeded the rates previously reported by the CDC [2] The highest troponin elevations were seen in the 16-17-year-old boys and girls. In the setting of cardiac symptoms, children with elevated troponin levels have a high likelihood of cardiac disease. [17, 18] Of note, the threshold for normal levels in children may be even lower than the 0.1 ng/mL used in adults. [17] To contextualize the benefits of vaccination for adolescents, we chose, as the CDC did [2, 3] to provide a benefit-harm analysis based on varying levels of COVID-19 hospitalization rates. [19] Our analysis not only considered circulating disease levels but also the presence of individual risk factors for severe disease. A weakness of our analysis was not being able to stratify hospitalization risks for children with and without natural immunity. The CDC estimated that on May 29th, 2021, that 36.2% [15] of all children had already been infected with SARS-CoV-2.

This estimate was made 16 months into the pandemic, thus adjusting for the current time (19 months), the current estimate would be (19/16)*36.2% = 42.9% of children previously infected.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 8, 2021. ; https://doi.org/10.1101/2021.08.30.21262866 doi: medRxiv preprint Absolute infection-hospitalization rates for children with and without medical comorbidities and with and without history of infection have yet to be established.

In a recent report [20] of 15 patients aged 12-18 hospitalized with post-vaccination myocarditis, the clinical course was reported to be relatively benign, but 1/15 had abnormal echocardiogram on follow-up and 4/15 had ongoing symptoms post-discharge. The CDC reported [2] that 218 of the 323 (67.5%) cases of myo/pericarditis in vaccine recipients <30 years were known to have had resolution of symptoms. Another study [21] found 16/23 (70%) males with vaccinationassociated myocarditis to have had resolution of symptoms within a week. Long-term sequalae of myocarditis is unknown; follow-up of this vaccine-associated condition is warranted.

COVID-19 has also been found to result in symptomatic myocarditis in 0.3% of collegiate athletes, [22] but its rate in children post-COVID-19 infection has not been well described. The one existing study [23] is limited by an inappropriately small denominator due to apparent underestimate of COVID-19 disease incidence during the study period. The study [23] reported only six post-COVID myocarditis cases in boys ages 12-17 over the course of a year in a 60million patient catchment area. Children have in general been spared from the worst effects of COVID-19. The reported mortality rate in England has so far been 2/million children [24, 25] , which may translate to around 6/million infections based on a prior infection rate of 1/3. [15] In the US, there have been 4404 multisystem-inflammatory syndrome in children (MIS-C) cases in a population of 74 million. [26] Long-duration of symptoms post-COVID-19 also appears less frequent in children than initially feared, with 1.8% of children with symptomatic COVID-19 experiencing at least one symptom two months after infection compared with 0.9% of negatively . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 8, 2021. ; https://doi.org/10.1101/2021.08.30.21262866 doi: medRxiv preprint tested controls after one month. [27] A thorough understanding of vaccine safety is thus crucial in this age group, especially for children without known risk factors for severe COVID-19 and those with history of infection. This report only outlines rates associated with the Pfizer-BioNTech. A recent report from Canada [28] suggests a greater than 2-fold higher rate of postvaccination myocarditis from the Moderna mRNA vaccine compared to the Pfizer-BioNTech mRNA vaccine. The most recent CDC update [6] also found Moderna to have higher rates of post-vaccination myocarditis than Pfizer-BioNTech in all male age groups except those [16] [17] years and those 65 and older.

A concern about using VAERS for our data analysis is the risk of over-ascertainment of a safety signal due to the open access system. To address this concern, we aligned our inclusion criteria with the CDC's case definition for probable myocarditis. Our rate of myocarditis postvaccination of 94.0/million was more than two times lower than that reported by the FDA (200/million) [2] and yet 31.5% higher than the CDC. This suggests that both VAERS and CDC are providing an underestimate of the true incidence of this condition. Furthermore, the reports in VAERS reviewed for this study were of children with myocarditis with cardiac symptoms and not cases of incidental cardiac inflammation noted on imaging. It is thus unclear how large of an underestimate of CAE incidence this report provides.

We, like the CDC, used a 120-day COVID-19 hospitalization rate as a meaningful comparator to vaccination-related harms, but this type of harm-benefit analysis does not take into account any benefits the vaccine provides against transmission to others, long-term COVID-19 disease risk or protection from non-severe COVID-19 symptoms. With this in mind, the risk of CAE for a boy . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 8, 2021. ; https://doi.org/10.1101/2021.08.30.21262866 doi: medRxiv preprint receiving his second dose of the vaccine is 2 to 6 times higher than the 120-day risk of hospitalization in boys 12-17 without underlying medical conditions. For boys with medical comorbidities, the 120-day COVID hospitalization rates are slightly higher than their rate of CAE if not adjusting for possible 40% overestimate of hospitalization rates [9, 13, 14] , in which case the rate of CAE would be slightly higher than 120-day hospitalization [ Figures 6 and 7 ].

As of the last week of August 2021, hospitalization rates for children ages 12-17 in the United States continued to approximate the moderate rate shown in Figures 6 and 7. [8] Current pediatric hospitalization rates are also a product of increasing natural infection and vaccination rates.

Overall pediatric case hospitalization rate from COVID-19 has been estimated by the CDC [15] and American Academy of Pediatrics [19] to be 0.8-0.9%, irrespective of comorbidities and not adjusting for possible 40% overestimate of hospitalization rates [9, 13, 14] . This rate has remained consistent through August of 2021.

Given the nearly fivefold disparity in risk of hospitalization for adolescents with and without comorbidities, it is important that the benefits of vaccination be clearly weighed and conveyed in the context of the unique health risks of the individual and the household. The benefits of vaccination in previously-infected children should be further studied and a harm-benefit analysis performed. A history of SARS-CoV-2 infection may be found to provide similar or superior immunity to vaccination [29] . A recent study [30] found a 4-fold increased risk of postvaccination myocarditis in those who had previously been infected with SARS-CoV-2.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 8, 2021. ; https://doi.org/10.1101/2021.08. 30.21262866 doi: medRxiv preprint In light of the vaccine-associated cardiac harms described in this report, further research as well as transparency about possible vaccine-related harms in relation to an individual child's COVID-19 risks is indicated. Alternate vaccination types, dosing or strategies, such as those that take a history of infection into consideration, may eventually be found to be more appropriate in this age group.

Our report found post-vaccination CAE rates following dose two of 162.2 and 94.0/million for boys 12-15 and 16-17, respectively. For boys with no underlying health conditions, the chance of either CAE, or hospitalization for CAE, after their second dose of mRNA vaccination are considerably higher than their 120-day risk of COVID-19 hospitalization, even at times of peak disease prevalence. The long-term consequences of this vaccine-associated cardiac inflammation

are not yet fully defined and should be studied. In lieu of pediatric vaccination mandates, the US may: 1) consider gathering data on previous infection in this age group and/or 2) follow the example of Germany, [31] Sweden [32] , Norway [33] and the WHO [34] and hold off on definitively recommending vaccination of low-risk children against COVID-19, or 3) offer one dose to adolescents as the UK has just announced [35] while more information about risks, benefits, harms and alternative dosing or vaccination strategies are studied and considered.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted September 8, 2021. ; https://doi.org/10.1101/2021.08.30.21262866 doi: medRxiv preprint Figure 6 . Harm-benefit analysis for second dose of mRNA vaccine vs. COVID-19 hospitalization for boys ages 12-17 in the context of disease incidence and presence of >1 comorbidity.

Darker shading denotes vaccine-associated risk of myocarditis equivalent to or exceeds disease-associated hospitalizations. hospitalization risk in the context of disease prevalence and presence of >1 comorbidity.

Israel sees probable link between Pfizer vaccine and myocarditis cases

Centers for Disease Control and Prevention. Advisory Committee for Immunization Practices

COVID-19 mRNA vaccines in adolescents and young adults: Benefit-risk discussion. Centers for Disease Control and Prevention. Advisory Committee for Immunization Practices

Summary for regulatory action

Centers for Disease Control and Prevention. Vaccination Demographics Trends

Myopericarditis following COVID-19 vaccination: Updates from the Vaccine Adverse Event Reporting System (VAERS)

C4591001 Clinical Trial Group. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

COVID-NET: COVID-19-Associated Hospitalization Surveillance Network

Hospitalization of Adolescents Aged 12-17 Years with Laboratory-Confirmed COVID-19 -COVID-NET, 14 States

Prevalence and Costs of Five Chronic Conditions in Children

A national profile of caregiver challenges among more medically complex children with special health care needs

Characteristics of Hospitalized Children Positive for SARSCoV-2: Experience of a Large Center

For COVID" or "With COVID": Classification of SARS-CoV-2. Hospitalizations in Children

Association of Age With Likelihood of Developing Symptoms and Critical Disease Among Close Contacts Exposed to Patients With Confirmed SARS-CoV-2 Infection in Italy

Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study

Value of Troponin Testing for Detection of Heart Disease in Previously Healthy Children

Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children

Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military

Prevalence of Clinical and Subclinical Myocarditis in Competitive Athletes With Recent SARS-CoV-2 Infection: Results From the Big Ten COVID-19 Cardiac Registry

Risk of Myocarditis from COVID-19 Infection in People Under Age 20: A Population-Based Analysis

Deaths in Children and Young People in England following SARS-CoV-2 infection during the first pandemic year: a national study using linked mandatory child death reporting data

Emergence of SARS-CoV-2 Alpha (B.1.1.7) variant, infection rates, antibody seroconversion and seroprevalence rates in secondary school students and staff: active prospective surveillance

Health Department-Reported Cases of Multisystem Inflammatory Syndrome in Children (MIS-C) in the United States

Illness duration and symptom profile in a large cohort of symptomatic UK school-aged children tested for SARS-CoV-2. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. Lancet Child Adolesc Health

Adverse Events Following Immunization (AEFIs) for COVID-19 in Ontario: December 13

Comparing SARS-CoV-2 natural immunity to vaccineinduced immunity: reinfections versus breakthrough infections

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting

German panel gives limited approval for COVID-19 shot for adolescents

Children and adolescents. -information about vaccination against COVID-19. Public Health Agency of Sweden

COVID-19 advice for the public: getting vaccinated

JCVI statement on COVID-19 vaccination of children and young people aged 12 to 17 years: 15